What DBV Technologies (DBVT) Said on Its Q3 Earnings Call

DBV Technologies NASDAQ: DBVT said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing preparations for a potential commercial launch and addressing manufacturing readiness at its contract manufacturing partner.

MarketBeat • a day ago

DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript

DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript

Seeking Alpha • 21 hours ago

DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update

Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review Accelerated Commercial Readiness towards the launch of the VIASKIN® Peanut Patch in children aged 4-7 years in the US, if approved Reported cash and cash equivalents of $165.7 million as of September 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, October 28, at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage specialty biopharmaceutical company, today reported financial results for the Third Quarter of 2026. The quarterly and nine months financial statements were approved by the Board of Directors on October 28, 2026.

GlobeNewsWire • Oct 28, 2026

DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026

Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Wednesday, October 28th, at 5:00 p.m. ET to review its third quarter 2026 financial results and provide a business update.

GlobeNewsWire • Oct 27, 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population.  DBV has requested Priority Review of the BLA.

GlobeNewsWire • Sep 29, 2026

DBV Technologies to Participate in Upcoming September Investor Conferences

Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September: 2026 Cantor Global Healthcare Conference – September 9, 2026 Format:         Fireside Chat Time:            1:00pm ETLocation:       New York, NY Citi's 2026 Biopharma Back to School Conference – September 10, 2026 Format:         1 on 1 MeetingsLocation:       New York, NY H.C. Wainwright 28 th Annual Global Investment Conference – September 15, 2026 Format:         Fireside ChatTime:            3:00pm ETLocation:      New York, NY Live webcasts of the fireside chats will be available on the Events section of the Company's website here and will be available for 90 days after the event.

GlobeNewsWire • Sep 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

Information Regarding the Total Number of Voting Rights and  Total Number of Shares of the Company as of August 31, 2026

GlobeNewsWire • Sep 2, 2026

Artisan International Small-Mid Fund Q2 2026 Portfolio Review

Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.

Seeking Alpha • Aug 24, 2026

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $50 million, before deducting sales agent commissions and offering expenses payable by the Company, to RA Capital Management, L.P (“RA Capital”) through Citizens JMP Securities, LLC (“Citizens”), acting as sales agent. Each ADS represents the right to receive five Ordinary Shares of the Company.

GlobeNewsWire • Jul 30, 2026

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

DBV Technologies is rated Buy following positive Phase 3 VITESSE results. My risk- and dilution-adjusted DCF yields $42 per ADS, more than double the current share price. The model assumes that 60% of diagnosed children with adequate insurance coverage ultimately initiate treatment, reflecting Viaskin's favorable safety profile, user-friendly administration, and the significant burden of avoidance-only management. An initial backlog of untreated children creates a temporary annual revenue peak above $1.6bn before revenues stabilize around $1bn as the market reaches steady state.

Seeking Alpha • Jul 26, 2026